Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Canabiis Use Disorder Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Canabiis Use Disorder (CUD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Canabiis Use Disorder Research. Learn more about our innovative pipeline today! @ Canabiis Use Disorder Pipeline Outlook- https://www.delveinsight.com/sample-request/Canabiis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Canabiis Use Disorder Pipeline Report
• In May 2025, University of Massachusetts, Worcester conducted a study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, or cannabis). Thirty-nine participants will be randomly assigned to switch to brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the control group). The study will be conducted at 4 sites in the US. The investigators expect to enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site. Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina at Chapel Hill (UNC).
• DelveInsight's Canabiis Use Disorder pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Canabiis Use Disorder treatment.
• The leading Canabiis Use Disorder Companies such as Aelis Farma, Anebulo Pharmaceuticals, Indivior, and others.
• Promising Canabiis Use Disorder Therapies such as APH-1501, 3ß-(4-methoxybenzyloxy) pregn-5-en-20-one, and others.

Stay informed about the cutting-edge advancements in Canabiis Use Disorder treatments. Download for updates and be a part of the revolution in care @ Canabiis Use Disorder Clinical Trials Assessment- https://www.delveinsight.com/sample-request/Canabiis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Canabiis-Use-Disorder Emerging Drugs
• AEF 0117: Aelis Farma
AEF0117 is the first drug candidate of the new pharmacological class of CB1-SSi, a rationally designed analog of pregnenolone, the naturally occurring steroid hormone that binds to a specific site on the CB1 receptor. Pregnenolone and AEF0117 do not modify the binding of agonists to the CB1 but only block certain signaling pathways activated by agonists, such on the CB1. Through this selective mechanism of action, AEF0117 potently inhibits behavioral effects without altering normal behavior. Unlike pregnenolone, AEF0117, is highly bioavailable when taken orally, exhibits favorable pharmacokinetic properties for once-daily administration, and is not converted into other steroids. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Canabiis use disorder.

Learn more about Canabiis Use Disorder Drugs opportunities in our groundbreaking Canabiis Use Disorder Research and development projects @ Canabiis Use Disorder Unmet Needs- https://www.delveinsight.com/sample-request/Canabiis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Canabiis Use Disorder Companies
Aelis Farma, Anebulo Pharmaceuticals, Indivior, and others.

Canabiis-Use-Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Canabiis Use Disorder Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Canabiis Use Disorder Treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Canabiis Use Disorder Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/Canabiis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Canabiis Use Disorder Pipeline Report
• Coverage- Global
• Canabiis Use Disorder Companies- Aelis Farma, Anebulo Pharmaceuticals, Indivior, and others.
• Canabiis Use Disorder Therapies- APH-1501, 3ß-(4-methoxybenzyloxy) pregn-5-en-20-one, and others.
• Canabiis Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Canabiis Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Canabiis Use Disorder Pipeline on our website @ Canabiis Use Disorder Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/Canabiis-use-disorder-cud-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Canabiis-Use-Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Canabiis-Use-Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name : Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. AEF 0117: Aelis Farma
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug Name : Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. INDV-5004: Indivior
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Canabiis-Use-Disorder Key Companies
21. Canabiis-Use-Disorder Key Products
22. Canabiis-Use-Disorder- Unmet Needs
23. Canabiis-Use-Disorder- Market Drivers and Barriers
24. Canabiis-Use-Disorder- Future Perspectives and Conclusion
25. Canabiis-Use-Disorder Analyst Views
26. Canabiis-Use-Disorder Key Companies
27. Appendix

About Us

DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and pharma sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.